Healthcare
Quest PharmaTech Inc.(QPTFF)
Live Price
Offline$0.031
+0.00% today
Window Change
+128.57%
Window
Jun 23, 2025 โ May 15, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +40.4%
- Dividend Yield
- 0.0%
Coverage: 227 bars ยท Jun 23, 2025 โ May 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Quest PharmaTech Inc. (QPTFF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.03 and up 128.6% across the available one-year price window (Jun 23, 2025 โ May 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +40.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +40.4%, free cash flow -49.5% with operating margin 0.0% and ROIC -2.8%. Stock Foundry combines QPTFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 28, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +40.4%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Sep 29, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Jun 26, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 May 28, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QPTFF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
QPTFF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for QPTFF and SPY.
Company Overview
Quest PharmaTech Inc.
Other OTC
Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer. Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; skin penetrating active molecules for cosmetic and pharmaceutical use; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
- Leadership
- Ragupathy Madiyalakan
- IPO Date
- Aug 24, 2018
- Employees
- 3
- Street Address
- 8123 Roper Road NW
- Mailing
- Edmonton, AB, T6E 6S4
- Region
- Edmonton, AB, CA
- Reporting Currency
- USD
- Investor Line
- +1 780 448 1400
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 0.3
Growth
- Revenue
- 0.0%
- EPS
- +40.4%
- Free Cash Flow
- -49.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -1.7%
- ROIC
- -2.8%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 0.07
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.